Genmab Plunges as Investor Sells 5.5% Stake: Copenhagen Mover
This article is for subscribers only.
Genmab A/S, the Danish company developing cancer drugs, fell the most in 14 months in Copenhagen trading after an investor offered to sell a 5.5 percent stake at a price below yesterday’s close.
Genmab dropped as much as 14 percent, the most since April